Archive

November 21, 2025

Browsing

The post Coinbase to Acquire Solana Trading Platform Vector to Expand On-Chain Access appeared first on Coinpedia Fintech News

Coinbase, the leading crypto exchange, is planning yet another acquisition in what’s shaping up to be its most active year for M&A deals. In a recent blog post, the exchange announced that it has entered into an agreement to acquire Vector, an on-chain trading platform built on Solana.

Expanding On-Chain Trading

This move will give traders access to one of crypto’s most active, high-velocity trading ecosystems. According to Messari, Solana’s decentralized exchange (DEX) volume for 2025 has already crossed $1 trillion. 

“This acquisition will help make Coinbase the best place to trade by broadening asset availability and improving the experience of trading assets through our DEX trading integration in Coinbase,” the exchange said.

Vector’s team brings deep Solana-native expertise and technology that can detect new assets as soon as they are created on-chain or launched via major launchpads. This technology will integrate into Coinbase’s DEX to improve speed, liquidity, and access to a wider range of assets across the Solana ecosystem.

Currently, users can only trade tokens on exchanges built on Coinbase’s own blockchain, Base. The exchange hopes to further expand access to Solana. The deal is expected to close by the end of the year, pending the customary closing requirements.

As part of this integration, its current mobile and desktop apps will be discontinued. Tensor Foundation, which governs the Tensor protocol, will stay independent and continue to oversee the Tensor NFT marketplace and its native token, which will also remain independent and unaffiliated with Coinbase.

Towards an “Everything Exchange”

“The Coinbase app is really meant to be an agnostic platform to enable people to trade all of the assets they want to trade,” Max Branzburg, Coinbase’s vice president of product management, told Fortune

Branzburg emphasized that combining Vector’s depth with Coinbase’s scale will unlock a new chapter of open, accessible, global trading.

Coinbase is working towards becoming an “everything exchange”, a single platform where users can trade everything on-chain with faster, cheaper, and always-accessible markets. 

Growing Trend in Crypto M&A

Notably, this marks Coinbase’s ninth acquisition in 2025.

It bought the crypto derivatives exchange Deribit for $2.9 billion in May, and in October, it paid $375 million for the ICO platform Echo. It also planned to buy the stablecoin company BVNK for around $2 billion. However, that deal was called off in November.

Coinbase is not the only one buying startups. In the third quarter of 2025, crypto mergers and acquisitions topped $10 billion, according to Architect Partners.

U.S. stock markets were poised for lift off Thursday, after a strong earnings report from computer chip giant Nvidia signaled that there is still plenty of room to run in the artificial intelligence boom that has powered markets higher for much of the year.

Prior to the opening bell, bets on the S&P 500 were up about 1%, while the tech-heavy Nasdaq climbed 1.5%.

Late Wednesday, Nvidia said sales of its trademark Blackwell AI chips ‘are off the charts,’ while another set of key computer processing units is ‘sold out,” founder and CEO Jensen Huang said in a statement.

On a call with investors following the report, Huang dismissed concerns about an AI bubble.

“There’s been a lot of talk about an AI bubble. From our vantage point, we see something very different,” Huang said.

Dan Ives, managing director at Wedbush Securities finanical group, echoed that sentiment.

“This was a golden quarter for Nvidia with demand massive and well above Street whisper numbers,’ Ives said in an email. ‘These numbers validate the AI Revolution is still early days and send the bears back into hibernation mode.’

Shares of the world’s most valuable company were up more than 4% in after-hours trading.

Nvidia’s chips have been the catalysts for a massive build-out of data centers that have supplied a backbone to the U.S. economy amid slowdowns elsewhere. More money is flowing into building data centers than all other manufacturing facility types combined, according to the research group S&P Global.

Until recently, that spending has also powered major stock indexes to record highs.

Lately, however, stocks have shown signs of wobbling lately. The declines in share prices — led by tech companies — have sparked debates about whether AI-driven gains are beginning to slow.

This raises a bigger question: how the broader economy will perform if it no longer benefits from all the wealth the AI boom is creating.

Nvidia’s latest earnings are likely to allay these fears, for now at least.

Huang said last month that his company had $500 billion in orders for its chips, for 2025 and 2026 combined.

“This is how much business is on the books. Half a trillion dollars’ worth so far,” Huang said at a conference in Washington, D.C.

Alongside broader concerns about the state of the U.S. economy, stock market momentum has been tripped up by worries about circular dealing among AI’s biggest players. This means the same money is being passed back and forth between several companies — even as each company’s individual value climbs.

Nvidia is a fixture in the kinds of deals that are raising concerns. It recently announced a commitment alongside Microsoft to fund AI software provider Anthropic with $10 billion.

Nvidia CEO Jensen Huang during the Live Keynote Pregame of the Nvidia GPU Technology Conference in Washington on Oct. 28.Jim Watson / AFP – Getty Images file

This kind of big collaboration news would typically boost the stock prices of all the companies involved. But neither Nvidia’s nor Microsoft’s stock got a boost from the Anthropic announcement.

Analysts with Deutsche Bank said this is a sign of the ongoing investor wariness about deals like this.

“It goes to show how sentiment has turned more negative in the last few weeks, with the circular AI deals being treated with increasing caution as the conversation around a potential bubble has gathered pace,” they wrote in a note published Wednesday.

The Nvidia headquarters, in Santa Clara, Calif., on May 21, 2024.Justin Sullivan / Getty Images file

The question now is whether the latest market hiccups represent a temporary pullback, or the onset of a more permanent state of affairs.

For the experts who are cautiously optimistic that the market will continue to climb, Nvidia’s massive haul serves to validate their rosy outlook.

“We think the investment boom has room to run,” Goldman Sachs researchers wrote in a note published Wednesday, adding that the economy writ large has remained resilient, something that should provide ongoing support to stock returns.

This post appeared first on NBC NEWS

Eli Lilly crossed into historic territory on Friday, becoming the first healthcare company ever to hit a $1 trillion market valuation.

Shares rose 1.7% to mark the milestone, cementing the Indianapolis pharmaceutical giant as Wall Street’s newest mega-cap champion.

With stock gains exceeding 36% year-to-date, Lilly has dramatically outpaced tech volatility and signaled a major investor rotation toward defensive, high-growth healthcare plays, especially as mega-cap tech faces mounting questions about valuations and returns.

The GLP-1 goldmine: How obesity drugs minted a trillion-dollar giant

Lilly’s ascent rests almost entirely on two blockbuster drugs: Mounjaro, which treats type 2 diabetes, and Zepbound, the weight-loss injection.

Together, they’re rewriting pharmaceutical economics. In Q3 2025, the duo generated $10.1 billion in combined revenue, more than 57% of Lilly’s total $17.6 billion quarterly sales.

Mounjaro nearly doubled to $6.52 billion, crushing analyst expectations of $5.51 billion, while Zepbound nearly tripled to $3.57 billion, topping estimates of $3.5 billion.​

The commanding market share tells the real story. Lilly now captures nearly 60% of all US GLP-1 prescriptions, compared to competitor Novo Nordisk, which commands just 42%.

This dominance reflects both superior drug efficacy; Mounjaro’s dual-action mechanism outperforms Novo’s single-target semaglutide and Lilly’s aggressive direct-to-consumer strategy.

The Walmart partnership to sell Zepbound vials at lower cash prices has particularly resonated with price-sensitive patients.​

Wall Street projects breathtaking growth ahead.

Analysts estimate the weight-loss drug market could reach $150 billion by the early 2030s, with Truist Securities predicting Lilly’s obesity portfolio, including the upcoming oral drug orforglipron, due early 2026, could hit $101 billion in peak worldwide revenue.

A White House pricing deal on GLP-1s could unlock another 40 million Medicare patients, dramatically expanding the addressable market size.

Once considered niche, obesity treatment has become the most profitable healthcare category.​

Beyond obesity: Why Lilly is the ‘new magnificent seven’ for risk-averse investors

Lilly’s trillion-dollar valuation signals a fundamental shift in investor sentiment.

With mega-cap technology stocks under pressure over AI capex returns, Lilly offers what tech cannot: predictable, near-term revenue growth tied to an expanding addressable market.

The company trades at roughly 51x forward earnings, a premium, yes, but justified by recurring growth less vulnerable to semiconductor cycles or geopolitical whipsaw.​

CEO Dave Ricks is deliberately positioning Lilly as a long-term compounder.

His strategy includes an R&D partnership with Nvidia, launching a drug-discovery supercomputer in January 2026, signaling intent to extend innovation pipelines beyond the patent cliff.

The risks remain real: pricing pressures on Mounjaro and execution risks on orforglipron could test momentum.

But for now, Lilly has captured the market imagination as the anti-tech mega-cap story, rare validation for healthcare in a tech-dominated era.

The post Wall Street’s new darling: Eli Lilly becomes healthcare’s first $1 trillion powerhouse appeared first on Invezz